Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS in Sepsis-related Organ Dysfunction
NCT03925857Phase 1Completed
- Sponsor
- Enlivex Therapeutics
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Allocetra in sepsis and multiple organ dysfunction syndrome (MODS) (2 arms), sponsored by Enlivex Therapeutics. Primary endpoint: Adverse Events and Serious Adverse Events at 28 days. Started Jan 2019; status: completed.
02
Drugs
Allocetra
03
Conditions
sepsismultiple organ dysfunction syndrome (MODS)
Beyond the preview
Go deeper on NCT03925857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925857.